CAMP4 Therapeutics (CAMP) shares Q3 2025 results in furnished 8-K press release

Rhea-AI Filing Summary

CAMP4 Therapeutics Corporation furnished an update on its business by providing investors with its financial results for the quarter ended September 30, 2025. The company reported these quarterly results through a press release dated November 6, 2025, which is attached as Exhibit 99.1.

The 8-K clarifies that the press release and related information are considered “furnished” rather than “filed” under securities laws, which limits certain legal liabilities and controls how the information may be incorporated into other regulatory documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001736730false00017367302025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

CAMP4 THERAPEUTICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-42365

81-1152476

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

One Kendall Square Building 1400 West, 3rd Floor Cambridge, MA

02139

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 651-8867

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CAMP

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release issued by CAMP4 Therapeutics Corporation on November 6, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CAMP4 THERAPEUTICS CORPORATION
			By:			/s/ Josh Mandel-Brehm
						Name: Josh Mandel-Brehm
						Title:   President and Chief Executive Officer

Date: November 6, 2025

FAQ

What did CAMP4 (CAMP) disclose in this 8-K filing?

CAMP4 Therapeutics disclosed that it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is treated as furnished, not filed, under securities law.

Which period’s results are covered in CAMP4’s latest 8-K?

The 8-K covers CAMP4 Therapeutics’ financial results for the quarter ended September 30, 2025. These results are contained in a press release dated November 6, 2025 and included as Exhibit 99.1 to the report.

How is CAMP4’s Q3 2025 press release treated under securities laws?

CAMP4 states that the press release and related information are furnished, not filed, under Section 18 of the Exchange Act. This limits certain liabilities and affects how the information can be incorporated into other SEC filings.

Where can investors find CAMP4’s Q3 2025 financial press release?

Investors can find CAMP4 Therapeutics’ Q3 2025 financial press release as Exhibit 99.1 to the 8-K. The exhibit contains the detailed quarterly results for the period ended September 30, 2025, dated November 6, 2025.

Who signed CAMP4’s November 6, 2025 8-K report?

The 8-K report was signed on behalf of CAMP4 Therapeutics Corporation by Josh Mandel-Brehm. He is identified as the company’s President and Chief Executive Officer in the signature block of the filing.